RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to hold cancer at bay, paving way for potentially curative CAR-T
Disease control Recruiting nowThis study is testing a two-drug combination (golcadomide and rituximab) as a 'bridge' treatment for adults with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The goal is to control the cancer and improve patients' health so they can proceed to a…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage trial is testing a new drug called tegavivint in patients with an aggressive type of lymphoma that has returned or stopped responding to other treatments. The main goals are to find a safe dose and understand the drug's side effects. Researchers hope the drug can…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA ACTIVATED B-CELL TYPE
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC